<DOC>
	<DOCNO>NCT02647554</DOCNO>
	<brief_summary>A Prospective , Multi-Centre , Double-Blind , Randomized , Placebo-Controlled , Trial Ulinastatin Treatment Adult Patients Sepsis Septic Shock China</brief_summary>
	<brief_title>Ulinastatin Treatment Adult Patients With Sepsis Septic Shock China</brief_title>
	<detailed_description>Investigational drug：Ulinastain Injection Study title： A Prospective , Multi-Centre , Double-Blind , Randomized , Placebo-Controlled , Trial Ulinastatin Treatment Adult Patients Sepsis Septic Shock China Principal Investigator：Professor Bin Du , Medical Intensive Care Unit , Peking Union Medical College Hospital ; Professor Xiangyou Yu , Critical Care Medicine , First Affiliated Hospital , Xinjiang Medical University Study subjects： Adult patient sepsis septic shock eligible inclusion inclusion criterion meet within 48 hour meet criterion sepsis-3 definition Study phase： Investigator Initiated Trial ( IIT ) Study objectives： The primary objective study determine whether ulinastatin , compare placebo , reduce 28-day all-cause mortality patient sepsis septic shock Study design： Prospective , Multi-Centre , Double-Blind , Randomized , Placebo-Controlled , Clinical Trial Medication method： - Ulinastain treatment group： 400,000 IU ulinastatin match placebo reconstitute 10 mL 0.9 % normal saline , dissolve 100 mL 0.9 % normal saline every 8 hour 10 day double-blind fashion . Intravenous infusion , The study drug infuse intravenously 1 hour . - Placebo control group：Matching medication Course：10 day Sample size： 348 ( 174 patient treatment group , 174 patient control group ) Sites： 15 Primary endpoint：The primary outcome measure study death cause 28-days . Secondary endpoint : - Mortality rate 90-days - Mortality rate ICU - Mortality rate hospital discharge - ICU-free day 28 day - Organ dysfunction assess Sequential Organ Failure Assessment ( SOFA ) score 1 , 3 , 6 , 10,14 , 28 day randomization - Incidence duration supportive care organ dysfunction include vasoactive agent , invasive noninvasive mechanical ventilation , continuous renal replacement therapy ( CRRT ) - Blood lactate concentration 1 , 3 , 6 10 day randomization - Condition fluid balance within 10 day randomization - High-sensitivity C-reactive protein ( hs-CRP ) , IL-6 , IL-10 , TNF-α 1 , 3,6 10 day randomization - ADL level hospital discharge Safety endpoints - adverse event - serious adverse event - vital sign , complete blood count , chemistry , electrocardiogram</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<mesh_term>Trypsin Inhibitors</mesh_term>
	<criteria>Patients eligible inclusion inclusion criterion meet 1 ) Sepsis3 criterion Society Critical Care Medicine ( SCCM ) /European Society Intensive Care Medicine ( ESICM ) 1 . Suspected confirmed infection AND 2 . Evidence acute organ dysfunction • patient know preexist organ dysfunction ( The baseline SOFA score assume zero ) : total SOFA score ≥2 point 48 hour infection 24 hour infection . • patient know preexist organ dysfunction ( The baseline SOFA score assume accord baseline condition ) : change total SOFA score ≥2 point 48 hour infection 24 hour infection . 2）48 hour within diagnosis sepsis 3）Signed date informed consent obtain prior screen procedure subject ( legal representative ) . If subject unable provide consent , could obtain legal representative accord local regulation . Consent subject obtain afterwards available . 4） Fertile men woman agree use efficient birth control method treatment period least 28 day last dose . Fertile define biologically fertile sexually active investigator 's view . 5） Nonchildbearing woman ( meet least one follow criterion ) : • Past hysterectomy bilateral oothectomy； • Medically confirm ovarian failure , menopause ( amenorrhea 12 month pathological physiological reason ) 1 ) Age &lt; 18 year , age &gt; 80 year 2 ) Pregnancy lactate 3 ) New York Heart Association Class IV congestive heart failure , nonseptic cardiogenic shock , uncontrolled acute blood loss 4 ) Severe , preexisting , parenchymal liver disease clinically significant portal hypertension , ChildPugh C stage cirrhosis acute liver failure 5 ) Receipt solidorgan bone marrow transplant 6 ) Advanced pulmonary fibrosis non invasive ventilation study entry 7 ) Myocardial infarction within previous 3 month 8 ) Cardiopulmonary resuscitation within 72 hour study entry 9） Invasive fungal infection active pulmonary tuberculosis 10 ) Fullthickness thermal chemical burn involve 30 % body surface area 11 ) Evidence significant drug diseaseinduced immunosuppression · Evidence moderate severe neutropenia , i.e . absolute neutrophil count ( ANC ) &lt; 1.0 x 10^9/L Administration high dos corticosteroid , i.e . dose &gt; 20 mg/day prednisone equivalent , ≥ 2 week immediately prior evaluation enrollment . Hydrocortisone dose ≤ 300 mg/d treatment septic shock acceptable . Immunomodulatory medication ( e.g . cyclosporine , azathioprine , OKT3 ) , chemotherapy , radiation therapy within 2 month study entry Known HIV seropositivity Any disease sufficiently advance suppress resistance infection Nonremission stage hematological/lymphoid tumor 12 ) Previous Xuebijing , thymosin IVIG Within 2 month study entry 12 ) Inability obtain informed consent assent 13 ) Participation investigational clinical trial within 6 month screen 14 ) Expected survival &lt; 2 month chronic vegetative state 15 ) Lack commitment full , aggressive , life support 16 ) History hypersensitivity ulinastatin excipients preservative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>Ulinastatin</keyword>
	<keyword>adult</keyword>
	<keyword>China</keyword>
</DOC>